Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Psychopharmacology
  4. Volume 12, Issue 1
  5. Article
Volume 12, Issue 1
  • ISSN: 2211-5560
  • E-ISSN: 2211-5579

Abstract

Parkinson's disease (PD) is a progressive neurological condition characterized by bradykinesia, rigidity, tremors, and impaired balance, among other motor impairments. The issue arises from dopaminergic neurons located in the spinal column of the brain. This research report examines the therapeutic potential of dopaminergic medications in the management of Parkinson's disease. The central concept of Parkinson's disease (PD) revolves around the notion that dopaminergic pathways exert significant influence over the regulation of movement. The book examines various dopaminergic medications, elucidating their mechanisms of action and the impact they exert on dopamine signaling. Examples of these medications include levodopa, dopamine agonists, and monoamine oxidase-B (MAO-B) inhibitors. Although dopaminergic medicines initially aid in the treatment of Parkinson's disease (PD), prolonged usage of these medications gives rise to several complications. Experiencing dyskinesias and motor fluctuations, characterized by episodes of involuntary movements and behaviors that are undesired, is a significant challenge. This study investigates the underlying causes of these difficulties and explores potential treatment options, including the use of controlled-release formulations and further therapy. The book discusses the non-motor symptoms of Parkinson's disease (PD), as well as the use of dopaminergic medications to treat mood disorders, autonomic dysfunction, and cognitive loss. Dopaminergic medications remain crucial in reducing motor symptoms and enhancing the quality of life for those with Parkinson's disease. Parkinson's disease (PD) is a complex condition with multiple distinct variations. In order to address its existing challenges and explore its potential implications for future Parkinson's disease medications, a comprehensive and effectively coordinated strategy is required.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpsp/10.2174/0122115560332182241031050521
2024-11-12
2025-06-27

  • From This Site

    /content/journals/cpsp/10.2174/0122115560332182241031050521
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. StokerT.B. BarkerR.A. Recent developments in the treatment of parkinson’s disease.F1000Res.9202010.12688/f1000research.25634.132789002
     [Google Scholar]
  2. KollerW.C. RuedaM.G. Mechanism of action of dopaminergic agents in Parkinson’s disease.Neurology199850Suppl 6S11S1410.1212/WNL.50.6_Suppl_6.S119633680
     [Google Scholar]
  3. VoonV. FernagutP.O. WickensJ. BaunezC. RodriguezM. PavonN. JuncosJ.L. ObesoJ.A. BezardE. Chronic dopaminergic stimulation in Parkinson’s disease: From dyskinesias to impulse control disorders.Lancet Neurol.20098121140114910.1016/S1474‑4422(09)70287‑X19909912
     [Google Scholar]
  4. EmamzadehF.N. SurguchovA. Parkinson’s disease: Biomarkers, treatment, and risk factors.Front. Neurosci.201812AUG61210.3389/fnins.2018.0061230214392
     [Google Scholar]
  5. AlexanderG.E. Biology of Parkinson’s disease: Pathogenesis and pathophysiology of a multisystem neurodegenerative disorder.Dialogues Clin. Neurosci.20046325928010.31887/DCNS.2004.6.3/galexander22033559
     [Google Scholar]
  6. SonneJ. ReddyV. BeatoM.R. Neuroanatomy, Substantia NigraStatPearls PublishingTreasure Island (FL)202230725680
     [Google Scholar]
  7. Juárez OlguínH. Calderón GuzmánD. Hernández GarcíaE. Barragán MejíaG. The role of dopamine and its dysfunction as a consequence of oxidative stress.Oxid. Med. Cell Longev.20162016973046710.1155/2016/973046726770661
     [Google Scholar]
  8. DiasV. JunnE. MouradianM.M. The role of oxidative stress in Parkinson’s disease.J. Parkinsons Dis.20133446149110.3233/JPD‑13023024252804
     [Google Scholar]
  9. MagrinelliF. PicelliA. ToccoP. FedericoA. RoncariL. SmaniaN. Pathophysiology of motor dysfunction in Parkinson’s disease as the rationale for drug treatment and rehabilitation.Parkinsons Dis.20162016983283910.1155/2016/983283927366343
     [Google Scholar]
  10. Gómez-BenitoM. GranadoN. García-SanzP. MichelA. DumoulinM. MoratallaR. Modeling Parkinson’s disease with the alpha-synuclein protein.Front. Pharmacol.20201135610.3389/fphar.2020.0035632390826
     [Google Scholar]
  11. JankovicJ. AguilarL.G. Current approaches to the treatment of Parkinson’s disease.Neuropsychiatr. Dis. Treat.20084474375710.2147/NDT.S200619043519
     [Google Scholar]
  12. StefanisL. α-Synuclein in Parkinson’s disease.Cold Spring Harb. Perspect. Med.201222a00939910.1101/cshperspect.a00939922355802
     [Google Scholar]
  13. GoldenbergM.M. Medical management of Parkinson’s disease.P T2008331059060619750042
     [Google Scholar]
  14. HaddadF. SawalhaM. KhawajaY. NajjarA. KaramanR. Dopamine and levodopa prodrugs for the treatment of parkinson's disease.Molecules23140201810.3390/molecules2301004029295587
     [Google Scholar]
  15. TambascoN. RomoliM. CalabresiP. Levodopa in Parkinson’s disease: Current status and future developments.Curr. Neuropharmacol.20181681239125210.2174/1570159X1566617051014382128494719
     [Google Scholar]
  16. SuskiV. StacyM. Dopamine AgonistsStatPearls PublishingTreasure Island (FL)202331869150
     [Google Scholar]
  17. AlborghettiM. NicolettiF. Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson’s Disease: From Bench to Bedside.Curr. Neuropharmacol.201917986187310.2174/1570159X1666618083010075430160213
     [Google Scholar]
  18. RivestJ. BarclayC.L. SuchowerskyO. COMT inhibitors in Parkinson's disease.Can. J. Neurol. Sci.199926Suppl 2S34S3810.1017/S031716710000007X10451758
     [Google Scholar]
  19. OssolaB. SchendzielorzN. ChenS.H. BirdG.S. TuominenR.K. MännistöP.T. HongJ.S. Amantadine protects dopamine neurons by a dual action: Reducing activation of microglia and inducing expression of GNDF in astroglia.Neuropharmacology201161457458210.1016/j.neuropharm.2011.04.03021586298
     [Google Scholar]
  20. HisaharaS. ShimohamaS. Dopamine receptors and Parkinson’s disease.Int. J. Med. Chem.2011201111610.1155/2011/40303925954517
     [Google Scholar]
  21. DeikA. Saunders-PullmanR. San LucianoM. Substance of abuse and movement disorders: Complex interactions and comorbidities.Curr. Drug Abuse Rev.20125324325310.2174/187447371120503024323030352
     [Google Scholar]
  22. ThanviB. LoN. RobinsonT. Levodopa-induced dyskinesia in Parkinson’s disease: Clinical features, pathogenesis, prevention and treatment.Postgrad. Med. J.20078398038438810.1136/pgmj.2006.05475917551069
     [Google Scholar]
  23. BorovacJ.A. Side effects of a dopamine agonist therapy for Parkinson’s disease: A mini-review of clinical pharmacology.Yale J. Biol. Med.2016891374727505015
     [Google Scholar]
  24. NavakauskienėR. Chapter 41 - Combination epigenetic therapy.Handbook of EpigeneticsElsevier2nd ed201762383210.1016/B978‑0‑12‑805388‑1.00041‑9
     [Google Scholar]
  25. LvQ. WangX. AsakawaT. WangX.P. Pharmacologic treatment of restless legs syndrome.Curr. Neuropharmacol.202119337238210.2174/1570159X1966620123015012733380302
     [Google Scholar]
  26. FaraoneS.V. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.Neurosci. Biobehav. Rev.20188725527010.1016/j.neubiorev.2018.02.00129428394
     [Google Scholar]
  27. O’ConnorA.D. MillsK.C. Monoamine oxidase inhibitors.Critical Care ToxicologySpringerCham BrentJ. BurkhartK. DarganP. HattenB. MegarbaneB. PalmerR. 201611810.1007/978‑3‑319‑20790‑2_28‑2
     [Google Scholar]
  28. StahlS.M. PradkoJ.F. HaightB.R. ModellJ.G. RockettC.B. Learned-CoughlinS. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor.Prim. Care Companion J. Clin. Psychiatry20046415916615361919
     [Google Scholar]
  29. WilkesS. The use of bupropion SR in cigarette smoking cessation.Int. J. Chron. Obstruct. Pulmon. Dis.200831455310.2147/COPD.S112118488428
     [Google Scholar]
  30. Methadone maintenance treatment.Clinical Guidelines for Withdrawal Management and Treatment of Drug Dependence in Closed SettingsWorld Health OrganizationGeneva
     [Google Scholar]
  31. YangP. PerlmutterJ.S. BenzingerT.L.S. MorrisJ.C. XuJ. Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?Ageing Res. Rev.20205710099410.1016/j.arr.2019.10099431765822
     [Google Scholar]
  32. KirkebyA. ParmarM. BarkerR.A. Strategies for bringing stem cell-derived dopamine neurons to the clinic.Prog. Brain Res.201723016519010.1016/bs.pbr.2016.11.01128552228
     [Google Scholar]
  33. Grall-BronnecM. Victorri-VigneauC. DonnioY. LeboucherJ. RousseletM. ThiabaudE. ZreikaN. DerkinderenP. Challet-BoujuG. Dopamine agonists and impulse control disorders: A complex association.Drug Saf.2018411197510.1007/s40264‑017‑0590‑628861870
     [Google Scholar]
  34. RobottomB. Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson’s disease.Patient Prefer. Adherence20115576410.2147/PPA.S1118221423589
     [Google Scholar]
  35. RegensburgerM. IpC.W. KohlZ. SchraderC. UrbanP.P. KassubekJ. JostW.H. Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: Practical considerations.J. Neural Transm. (Vienna)2023130684786110.1007/s00702‑023‑02623‑836964457
     [Google Scholar]
  36. CarboneF. DjamshidianA. SeppiK. PoeweW. Apomorphine for Parkinson’s disease: Efficacy and safety of current and new formulations.CNS Drugs201933990591810.1007/s40263‑019‑00661‑z31473980
     [Google Scholar]
  37. FarlowM.R. SomogyiM. Transdermal patches for the treatment of neurologic conditions in elderly patients: A review.Prim. Care Companion CNS Disord.2011136PCC.11r0114910.4088/PCC.11r0114922454804
     [Google Scholar]
  38. ZhuJ. ChenM. The effect and safety of ropinirole in the treatment of Parkinson disease.Medicine (Baltimore)202110046e2765310.1097/MD.000000000002765334797288
     [Google Scholar]
  39. ConstantinescuR. Update on the use of pramipexole in the treatment of Parkinson’s disease.Neuropsychiatr. Dis. Treat.20084233735210.2147/NDT.S232518728740
     [Google Scholar]
  40. BetteS. ShpinerD.S. SingerC. MooreH. Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: A review of the current clinical evidence.Ther. Clin. Risk Manag.2018141737174510.2147/TCRM.S13954530271159
     [Google Scholar]
  41. ChurchF.C. Treatment options for motor and non-motor symptoms of Parkinson’s disease.Biomolecules202111461210.3390/biom1104061233924103
     [Google Scholar]
  42. OgataN. de Souza DantasL.M. Crowell-DavisS.L. Selective Serotonin Reuptake InhibitorsTreasure Island (FL)StatPearls Publishing202332119293
     [Google Scholar]
  43. ZhangQ. AldridgeG.M. NarayananN.S. AndersonS.W. UcE.Y. Approach to cognitive impairment in Parkinson’s disease.Neurotherapeutics20201741495151010.1007/s13311‑020‑00963‑x33205381
     [Google Scholar]
  44. ChenJ.J. Treatment of psychotic symptoms in patients with Parkinson disease.Ment. Health Clin.20177626227010.9740/mhc.2017.11.26229955532
     [Google Scholar]
  45. RivasiG. RafanelliM. MosselloE. BrignoleM. UngarA. Drug-related orthostatic hypotension: Beyond anti-hypertensive medications.Drugs Aging2020371072573810.1007/s40266‑020‑00796‑532894454
     [Google Scholar]
  46. BuchfuhrerM.J. Strategies for the treatment of restless legs syndrome.Neurotherapeutics20129477679010.1007/s13311‑012‑0139‑422923001
     [Google Scholar]
  47. Lang-IllievichK. Bornemann-CimentiH. Opioid-induced constipation: A narrative review of therapeutic options in clinical management.Korean J. Pain2019322697810.3344/kjp.2019.32.2.6931091505
     [Google Scholar]
  48. PaulettiC. LocuratoloN. MannarelliD. MaffucciA. PetritisA. MeniniE. FattappostaF. Fatigue in fluctuating Parkinson’s disease patients: Possible impact of safinamide.J. Neural Transm. (Vienna)2023130791592310.1007/s00702‑023‑02654‑137210459
     [Google Scholar]
  49. BuhmannC. KassubekJ. JostW.H. Management of pain in Parkinson’s disease.J. Parkinsons Dis.202010Suppl 1S37S4810.3233/JPD‑20206932568113
     [Google Scholar]
  50. FreitasM.E. FoxS.H. Nondopaminergic treatments for Parkinson’s disease: current and future prospects.Neurodegener. Dis. Manag.20166324926810.2217/nmt‑2016‑000527230697
     [Google Scholar]
  51. MasoodN. Jimenez-ShahedJ. Effective management of “OFF” episodes in Parkinson’s Disease: Emerging treatment strategies and unmet clinical needs.Neuropsychiatr. Dis. Treat.20231924726610.2147/NDT.S27312136721795
     [Google Scholar]
  52. DeMaagdG. PhilipA. Part 2: Introduction to the pharmacotherapy of Parkinson’s disease, with a focus on the use of dopaminergic agents.P T201540959060026417179
     [Google Scholar]
  53. PandeyS. SrivanitchapoomP. Levodopa-induced dyskinesia: Clinical features, pathophysiology, and medical management.Ann. Indian Acad. Neurol.201720319019810.4103/aian.AIAN_239_1728904447
     [Google Scholar]
  54. SmithY. WichmannT. FactorS.A. DeLongM.R. Parkinson’s disease therapeutics: New developments and challenges since the introduction of levodopa.Neuropsychopharmacology201237121324610.1038/npp.2011.21221956442
     [Google Scholar]
  55. EspayA.J. BonatoP. NahabF.B. MaetzlerW. DeanJ.M. KluckenJ. EskofierB.M. MerolaA. HorakF. LangA.E. ReilmannR. GiuffridaJ. NieuwboerA. HorneM. LittleM.A. LitvanI. SimuniT. DorseyE.R. BurackM.A. KubotaK. KamondiA. GodinhoC. DaneaultJ.F. MitsiG. KrinkeL. HausdorffJ.M. BloemB.R. PapapetropoulosS. Technology in Parkinson’s disease: Challenges and opportunities.Mov. Disord.20163191272128210.1002/mds.2664227125836
     [Google Scholar]
  56. MittalK.R. PharasiN. SarnaB. SinghM. Rachana HaiderS. SinghS.K. DuaK. JhaS.K. DeyA. OjhaS. ManiS. JhaN.K. Nanotechnology-based drug delivery for the treatment of CNS disorders.Transl. Neurosci.202213152754610.1515/tnsci‑2022‑025836741545
     [Google Scholar]
  57. MahoneyJ.J. HanlonC.A. MarshalekP.J. RezaiA.R. KrinkeL. Transcranial magnetic stimulation, deep brain stimulation, and other forms of neuromodulation for substance use disorders: Review of modalities and implications for treatment.J. Neurol. Sci.202041811714910.1016/j.jns.2020.11714933002757
     [Google Scholar]
  58. AxelsenT.M. WoldbyeD.P.D. Gene therapy for Parkinson’s disease, An update.J. Parkinsons Dis.20188219521510.3233/JPD‑18133129710735
     [Google Scholar]
  59. Ul HassanA. HassanG. RasoolZ. Role of stem cells in treatment of neurological disorder.Int. J. Health Sci. (Qassim)20093222723321475541
     [Google Scholar]
  60. CarreraI. CacabelosR. Current drugs and potential future neuroprotective compounds for parkinson’s disease.Curr. Neuropharmacol.201917329530610.2174/1570159X1766618112712570430479218
     [Google Scholar]
  61. McCutcheonR.A. KrystalJ.H. HowesO.D. Dopamine and glutamate in schizophrenia: Biology, symptoms and treatment.World Psychiatry2020191153310.1002/wps.2069331922684
     [Google Scholar]
  62. TylerJ. ChoiS.W. TewariM. Real-time, personalized medicine through wearable sensors and dynamic predictive modeling: A new paradigm for clinical medicine.Curr. Opin. Syst. Biol.202020172510.1016/j.coisb.2020.07.00132984661
     [Google Scholar]
  63. VoraL.K. GholapA.D. JethaK. ThakurR.R.S. SolankiH.K. ChavdaV.P. Artificial intelligence in pharmaceutical technology and drug delivery design.Pharmaceutics2023157191610.3390/pharmaceutics1507191637514102
     [Google Scholar]
  64. TiwariG. TiwariR. BannerjeeS.K. BhatiL. PandeyS. PandeyP. SriwastawaB. Drug delivery systems: An updated review.Int. J. Pharm. Investig.20122121110.4103/2230‑973X.9692023071954
     [Google Scholar]
  65. WangR.C. WangZ. Precision medicine: Disease subtyping and tailored treatment.Cancers (Basel)20231515383710.3390/cancers1515383737568653
     [Google Scholar]
  66. SalehM. MarkovicM. OlsonK.E. GendelmanH.E. MosleyR.L. Therapeutic strategies for immune transformation in parkinson’s disease.J. Parkinsons Dis.202212Suppl 1S201S22210.3233/JPD‑22327835871362
     [Google Scholar]
  67. Rodriguez-MerchanE.C. The current role of disease-modifying osteoarthritis drugs.Arch. Bone Jt. Surg.2023111112236793668
     [Google Scholar]
  68. ChmielarzP. SaarmaM. Neurotrophic factors for disease-modifying treatments of Parkinson’s disease: Gaps between basic science and clinical studies.Pharmacol. Rep.20207251195121710.1007/s43440‑020‑00120‑332700249
     [Google Scholar]
  69. LeathemA. Ortiz-CerdaT. DennisJ.M. WittingP.K. Evidence for oxidative pathways in the pathogenesis of PD: Are antioxidants candidate drugs to ameliorate disease progression?Int. J. Mol. Sci.20222313692310.3390/ijms2313692335805928
     [Google Scholar]
  70. MonteiroM.C. ColemanM.D. HillE.J. PredigerR.D. MaiaC.S.F. Neuroprotection in neurodegenerative disease: From basic science to clinical applications.Oxid. Med. Cell Longev.20172017294910210.1155/2017/294910228337247
     [Google Scholar]
  71. MiyazakiI. AsanumaM. Multifunctional metallothioneins as a target for neuroprotection in Parkinson’s disease.Antioxidants202312489410.3390/antiox1204089437107269
     [Google Scholar]
  72. JohnsonK.B. WeiW.Q. WeeraratneD. FrisseM.E. MisulisK. RheeK. ZhaoJ. SnowdonJ.L. Precision medicine, AI, and the future of personalized health care.Clin. Transl. Sci.2021141869310.1111/cts.1288432961010
     [Google Scholar]
  73. GandhiK.R. SaadabadiA. Levodopa (L-Dopa)StatPearls PublishingTreasure Island (FL)202329489269
     [Google Scholar]
  74. WolfS.M. ThyagarajanB. FogelB.L. The need to develop a patient-centered precision medicine model for adults with chronic disability.Expert Rev. Mol. Diagn.201717541541810.1080/14737159.2017.130997628325089
     [Google Scholar]
  75. NakmodeD.D. DayC.M. SongY. GargS. The management of Parkinson’s disease: An overview of the current advancements in drug delivery systems.Pharmaceutics2023155150310.3390/pharmaceutics1505150337242745
     [Google Scholar]
  76. BohrA. MemarzadehK. Chapter 2 - The rise of artificial intelligence in healthcare applications.Artificial Intelligence in HealthcareAcademic Press2020256010.1016/B978‑0‑12‑818438‑7.00002‑2
     [Google Scholar]
  77. MadridJ. BenningerD.H. Non-invasive brain stimulation for Parkinson’s disease: Clinical evidence, latest concepts and future goals: A systematic review.J. Neurosci. Methods202134710895710.1016/j.jneumeth.2020.10895733017643
     [Google Scholar]
  78. GroissS.J. WojteckiL. SüdmeyerM. SchnitzlerA. Review: Deep brain stimulation in Parkinson’s disease.Ther. Adv. Neurol. Disord.20092637939110.1177/175628560933938221180627
     [Google Scholar]
  79. PirtošekZ. BajenaruO. KovácsN. MilanovI. ReljaM. SkorvanekM. Update on the management of Parkinson’s disease for general neurologists.Parkinsons Dis.20202020913147410.1155/2020/913147432300476
     [Google Scholar]
/content/journals/cpsp/10.2174/0122115560332182241031050521
Loading
The Present Difficulties and Potential Benefits of Dopaminergic Agents in Parkinson's Disease Treatment
Current Psychopharmacology 12, e22115560332182 (2024); https://doi.org/10.2174/0122115560332182241031050521
/content/journals/cpsp/10.2174/0122115560332182241031050521
/content/journals/cpsp/10.2174/0122115560332182241031050521
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): bradykinesia; dopaminergic agents; motor impairments; neurodegenerative disorder; Parkinson’s disease; substantia nigra

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test